Indication
AzaSite® (azithromycin ophthalmic solution) 1% is indicated for the treatment of bacterial conjunctivitis caused by the following organisms: CDC coryneform group G*, Staphylococcus aureus, Streptococcus mitis group, Streptococcus pneumoniae, and Haemophilus influenzae.
*Efficacy for this organism was studied in fewer than 10 infections.
Please report adverse events to FDA
Dosing RecommendationsThe recommended dosing regimen for AzaSite® is 1 drop twice a day for 2 days, followed by 1 drop once a day for the next 5 days, for a total of 9 drops per affected eye.
Important Safety Information For use as an eyedrop only. In clinical trials, the most common adverse event was eye irritation, which occurred in 1% to 2% of patients. Other adverse events (occurring in <1% of patients) were burning, stinging, and eye irritation upon instillation; skin irritation or rash; corneal erosion; dry eye; altered taste; nasal congestion; eye discharge; inflammation of the cornea; and sinus infection.
AzaSite® is a registered trademark of InSite Vision, Inc. All rights reserved. This site is published by Inspire Pharmaceuticals, Inc., which is solely responsible for its contents. It is intended for residents of the United States.
AZASITE.COM Privacy Policy | Terms & Conditions | Contact Us
Please read the full Prescribing Information before using AzaSite®
©2010 AZA-0383 Feburary 2010 Inspire Pharmaceuticals, Inc.